Literature DB >> 20616218

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

Brian A Walker1, Paola E Leone, Laura Chiecchio, Nicholas J Dickens, Matthew W Jenner, Kevin D Boyd, David C Johnson, David Gonzalez, Gian Paolo Dagrada, Rebecca K M Protheroe, Zoe J Konn, David M Stockley, Walter M Gregory, Faith E Davies, Fiona M Ross, Gareth J Morgan.   

Abstract

To obtain a comprehensive genomic profile of presenting multiple myeloma cases we performed high-resolution single nucleotide polymorphism mapping array analysis in 114 samples alongside 258 samples analyzed by U133 Plus 2.0 expression array (Affymetrix). We examined DNA copy number alterations and loss of heterozygosity (LOH) to define the spectrum of minimally deleted regions in which relevant genes of interest can be found. The most frequent deletions are located at 1p (30%), 6q (33%), 8p (25%), 12p (15%), 13q (59%), 14q (39%), 16q (35%), 17p (7%), 20 (12%), and 22 (18%). In addition, copy number-neutral LOH, or uniparental disomy, was also prevalent on 1q (8%), 16q (9%), and X (20%), and was associated with regions of gain and loss. Based on fluorescence in situ hybridization and expression quartile analysis, genes of prognostic importance were found to be located at 1p (FAF1, CDKN2C), 1q (ANP32E), and 17p (TP53). In addition, we identified common homozygously deleted genes that have functions relevant to myeloma biology. Taken together, these analyses indicate that the crucial pathways in myeloma pathogenesis include the nuclear factor-κB pathway, apoptosis, cell-cycle regulation, Wnt signaling, and histone modifications. This study was registered at http://isrctn.org as ISRCTN68454111.

Entities:  

Mesh:

Year:  2010        PMID: 20616218     DOI: 10.1182/blood-2010-04-279596

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  138 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma.

Authors:  F Li; L Hu; Y Xu; Z Li; S Yi; Z Gu; C Li; M Hao; K Ru; F Zhan; A Zetterberg; W Yuan; T Cheng; L Qiu
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

3.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

4.  Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

Authors:  Gang An; Yan Xu; Lihui Shi; Zhong Shizhen; Shuhui Deng; Zhenqing Xie; Weiwei Sui; Fenghuang Zhan; Lugui Qiu
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

5.  Loss of FAM46C Promotes Cell Survival in Myeloma.

Authors:  Yuan Xiao Zhu; Chang-Xin Shi; Laura A Bruins; Patrick Jedlowski; Xuewei Wang; K Martin Kortüm; Moulun Luo; Jonathan M Ahmann; Esteban Braggio; A Keith Stewart
Journal:  Cancer Res       Date:  2017-06-15       Impact factor: 12.701

6.  Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Authors:  Brian A Walker; Konstantinos Mavrommatis; Christopher P Wardell; T Cody Ashby; Michael Bauer; Faith E Davies; Adam Rosenthal; Hongwei Wang; Pingping Qu; Antje Hoering; Mehmet Samur; Fadi Towfic; Maria Ortiz; Erin Flynt; Zhinuan Yu; Zhihong Yang; Dan Rozelle; John Obenauer; Matthew Trotter; Daniel Auclair; Jonathan Keats; Niccolo Bolli; Mariateresa Fulciniti; Raphael Szalat; Philippe Moreau; Brian Durie; A Keith Stewart; Hartmut Goldschmidt; Marc S Raab; Hermann Einsele; Pieter Sonneveld; Jesus San Miguel; Sagar Lonial; Graham H Jackson; Kenneth C Anderson; Herve Avet-Loiseau; Nikhil Munshi; Anjan Thakurta; Gareth J Morgan
Journal:  Blood       Date:  2018-06-08       Impact factor: 22.113

7.  Common genetic variants related to genomic integrity and risk of papillary thyroid cancer.

Authors:  Gila Neta; Alina V Brenner; Erich M Sturgis; Ruth M Pfeiffer; Amy A Hutchinson; Briseis Aschebrook-Kilfoy; Meredith Yeager; Li Xu; William Wheeler; Michael Abend; Elaine Ron; Margaret A Tucker; Stephen J Chanock; Alice J Sigurdson
Journal:  Carcinogenesis       Date:  2011-06-03       Impact factor: 4.944

Review 8.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

Review 9.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14

10.  Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

Authors:  Angela Baker; Esteban Braggio; Susanna Jacobus; Sungwon Jung; Dirk Larson; Terry Therneau; Angela Dispenzieri; Scott A Van Wier; Gregory Ahmann; Joan Levy; Louise Perkins; Seungchan Kim; Kimberly Henderson; David Vesole; S Vincent Rajkumar; Diane F Jelinek; John Carpten; Rafael Fonseca
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.